Track topics on Twitter Track topics that are important to you
Third Rock Ventures has launched Casma Therapeutics with a $58.5m investment to harness the cellular process of autophagy to develop breakthrough therapies.
Scientists have known for decades that cells can recycle their own trash, but they’ve only recently started to figure out how. Casma Therapeutics is trying to prove that those insights could be usef...
Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.
Casma Therapeutics Inc. launched and concurrently raised $58.5mm in a Series A financing from Third Rock Ventures.
Third Rock launches Casma with $58.5 million A round to induce autophagy across a range of diseases.
“The body’s natural ability to perform autophagy declines with aging, which likely contributes to the aging process itself,” said Dr. Beth Levine, of UT Southwestern and Casma Therapeutics.
Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced a research collaboration with
ALDEX GS™ Tablets
ALDEX GS DMTablets
To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.
Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Casma Therapeutics is harnessing the natural cellular process of autophagy to open vast new target areas for drug discovery and development. Casma uses several approaches to inter...
Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...
Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...
Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...
Click Therapeutics, Inc. engineers, validates, and commercializes Digital Therapeuticsâ¢ solutions to benefit people with unmet medical needs through cognitive and neurobehavi...
We have published hundreds of Casma Therapeutics, Inc. news stories on BioPortfolio along with dozens of Casma Therapeutics, Inc. Clinical Trials and PubMed Articles about Casma Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Casma Therapeutics, Inc. Companies in our database. You can also find out about relevant Casma Therapeutics, Inc. Drugs and Medications on this site too.